NattoPharma buys MGP for $2.7M
Norwegian drugmaker NattoPharma ASA has acquired MGP Diagnostics AS for 17.2 million Norwegian krone ($2.7 million), resolving the conflict between them and securing a granted patent that is the key to the development of a new diagnostic test that may determine the need for the vitamin K2 product Mena Q7, NattoPharma's lead product.
The Lysaker-based company bought a total of 131,000 shares at 131 krone each from the previous owners: Anacott Steel AS (22.5%), Stein Westbye (22.5%), Leon Schurgers (22.5%), Cees Vermeer (22.5%) and VitaK (10%).
A wholly-owned subsidiary of the University of Maastricht, VitaK conducts most of NattoPharma's research on vitamin K2. The agreement gives the former company the right to 5% royalty of revenues generated by MGP, limited upwardly to 5.0 million krone per year and a total 40.0 million krone throughout the lifespan of the patent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze